MyoStrain

10/14/2025

Twenty years ago, the discovery of a biomarker forever changed the outlook for lung cancer patients.

It taught us a powerful lesson: the earlier we detect, the more lives we save.

Today, in cardiology, that same philosophy takes shape with MyoStrain®, a quick, non-invasive test that allows us to see what the clinical eye can’t yet perceive —
the first signs of cardiac muscle dysfunction, even when ejection fraction appears normal.

For oncology patients, MyoStrain is making a real difference, identifying cardiac damage before chemotherapy leaves irreversible effects.

💡 Early detection saves hearts, just as it once saved lungs.

And that is — once again — a silent revolution in medicine.

10/06/2025

This Breast Cancer Awareness Month, we celebrate patients and survivors—and recognize the importance of caring for the heart throughout cancer treatment.
Nearly 1 in 3 patients on anti-HER2 breast cancer therapy may face heart complications. That’s where innovations like MyoStrain® make a difference, giving doctors the ability to detect heart changes early and keep patients safe while they fight cancer.
Read more in The Role of Advanced Cardiovascular Imaging Modalities in Cardio-Oncology: https://bit.ly/3VM5MaJ

09/29/2025

Today on World Heart Day, we recognize the importance of early detection in protecting heart health worldwide.
Cardiac disease remains the leading cause of death globally, yet many conditions can be prevented or better managed when detected early. That’s where MyoStrain® plays a key role—providing clinicians with a fast, non-invasive way to detect subtle heart changes before symptoms appear.

09/15/2025

MyoStrain offers critical insights that inform proactive decision-making in cardiac care.

Let’s transform how we manage treatment to mitigate risk and prevent heart failure. Join us in redefining patient care for long-term health benefits.
Learn more: https://bit.ly/4fJsXM2

09/10/2025

Waiting for answers shouldn't be part of the journey to heart health. MyoStress® delivers rapid detection and accurate risk assessment for coronary artery disease suspects in just 15 minutes. No pharmacological stressors, no radiation – just efficient, individualized care.
Learn more here: https://bit.ly/45FQzg2

09/08/2025

Traditional heart metrics only scratch the surface of heart function, leaving physicians in the dark about the true impact of acute heart failure meds: https://bit.ly/3VcrNPG

MyoStrain® changes the game, offering precision and insight to guide personalized treatment strategies. Let's optimize care, reduce rehospitalizations, and enhance lives. Learn more here: https://bit.ly/4ncUng7

09/03/2025

An AHA study on the cardiotoxicity of anthracycline with and without immune checkpoint inhibitor (ICI) in treating high-risk early-stage triple negative breast cancer (TNBC) patients highlights encouraging results: no significant differences in cardiac events between the two groups. This opens doors for greater confidence in using ICIs in cancer care.

At Myocardial Solutions, we believe advanced imaging tools like MyoStrain® can play a crucial role in studies like this and in clinical practice. MyoStrain® offers early, non-invasive detection of subclinical cardiac dysfunction, helping physicians monitor heart health and guide treatment decisions for patients undergoing aggressive therapies: https://bit.ly/41iLnxo

For high-risk TNBC patients, precision tools like MyoStrain® can help ensure comprehensive care that prioritizes both cancer treatment and heart health.
Let’s continue the conversation on advancing cardio-oncology care.

08/28/2025

A new MESA study highlights the long-term impact of elevated blood pressure on myocardial structure and function—showing significant associations with impaired strain, increased LV mass, and fibrosis, even in non-hypertensive individuals.
While using our predecessor tagging-based MRI software, the study reinforces the need for objective tools like MyoStrain® to monitor myocardial dysfunction, assess treatment response, and guide early intervention in at-risk patients.
Learn more here: https://bit.ly/45IGOhg

08/25/2025

Thank you to everyone who joined us for the Radcliffe Cardiology webinar,
“Cardiac Magnetic Resonance Imaging in the Assessment of Cardiac Injury and Toxicity from Cancer‑Related Chemotherapy.”
Dr. Olga Toro-Salazar shared key insights on how cardiac MRI can detect early signs of chemotherapy-induced cardiotoxicity to help improve outcomes for cancer patients.

Join experts in this webinar on cardiac MRI's role in detecting heart toxicity from cancer chemotherapy. Ideal for healthcare professionals.

08/14/2025

We are pleased to announce that MyoStrain® will be featured in a live scanning demonstration at ESC 2025 using the Philips BlueSeal Mobile MRI.
Join us in Madrid for this exclusive, first-of-its-kind experience, showcasing how rapid, non-contrast, accessible cardiac MRI is expanding the boundaries of early detection and precision care.

Register for the VIP scanning session here: https://bit.ly/45psKZE

08/11/2025

Reliable, rapid cardiac assessment shouldn’t be limited by location. At ESC 2025, we’re demonstrating how MyoStrain®, in partnership with the Philips BlueSeal Mobile MRI, are reshaping access to advanced cardiac imaging.

Join us for a live scanning session and learn how we’re helping clinicians detect dysfunction earlier, with greater efficiency and precision, without contrast—wherever care is delivered.
Register now to reserve your spot: https://escinteractivecmrmyohealthtm.splashthat.com/

06/24/2025

This Men’s Health Month, we’re reminded that improving outcomes for men doesn’t start in the exam room it starts in our communities.

With MyoStrain®, clinicians can detect early heart dysfunction using a non-invasive, 10-minute cardiac MRI scan before symptoms ever appear. It’s fast, precise, and designed to support proactive care for men of all ages.

Together, we can create a culture of prevention, education, and empowerment.

🔗 Learn how MyoStrain® is helping communities protect heart health: https://bit.ly/43LBoCs